Case: Eli Lilly Canada Inc et al v Teva Canada Limited, 2017 FC 88
Drug: ZYPREXA® (olanzapine)
Nature of case: Action pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 (the Regulations)
Federal Court comments on the admissibility of ‘but for’ world s. 8 evidence and rejects generic pipefill claim
